Table 3.
Protein | SNP | Genotype | Number of patients | Age (yr) at onset of disease, median (range) | Colonic involvement at first examination (% of patients) | Fistulae during follow-up (% of patients) | Strictures during follow-up (% of patients) |
MMP-1 | -1607 1G/2G | 1G1G | 38 | 20.7 (0.3-45.6) | 52.6 | 71.1 | 84.2 |
1G2G | 54 | 22.4 (7.0-61.5) | 50 | 63 | 75.9 | ||
2G2G | 26-27 | 21.0 (3.4-40.2) | 57.7 | 63 | 70.4 | ||
MMP-2 | -1306 C/T | CC | 66-67 | 20.1 (5.8-61.5) | 57.6 | 64.2 | 74.6 |
CT+TT | 521 | 22.4 (0.3-50.1) | 46.2 | 67.3 | 80.8 | ||
MMP-3 | -1613 5T/6T | 5T5T | 34 | 22.4 (0.3-53.6) | 35.3a | 70.6 | 91.2a |
5T6T | 54 | 19.3 (3.4-61.5) | 63 | 66.7 | 74.1 | ||
6T6T | 30-31 | 23.5 (7.2-49.1) | 53.3 | 58.1 | 67.7 | ||
MMP-9 | -1562 C/T | CC | 88-89 | 21.0 (0.3-61.5) | 53.4 | 68.5 | 75.3 |
CT+TT | 301 | 22.7 (7.2-45.5) | 50 | 56.7 | 83.3 | ||
TIMP-1, ♂ | +372 T/C | T | 32 | 18.9 (0.3-48.3) | 53.1 | 78.1 | 87.5 |
C | 17 | 18.5 (5.9-61.5) | 52.9 | 76.5 | 94.1 | ||
TIMP-1, ♀ | +372 T/C | TT | 29 | 24.3 (7.0-56.8) | 55.2 | 41.4c | 69.0 |
TC | 22-23 | 23.5 (3.4-39.6) | 45.5 | 69.6 | 78.3 | ||
CC | 18 | 22.2 (10.4-49.1) | 55.6 | 66.7 | 55.6 | ||
TIMP-2 | +303 G/A | GG | 91-92 | 21.5 (0.3-61.5) | 56.0 | 68.5 | 77.2 |
GA+AA | 271 | 22.4 (3.4-56.8) | 40.7 | 55.6 | 77.8 | ||
TNF-α | -308 G/A | GG | 79-80 | 22.6 (0.3-61.5) | 50.6 | 68.8 | 78.8 |
GA+AA | 391 | 18.9 (3.4-45.5) | 56.4 | 59.0 | 74.4 |
Only 7, 1, 2 and 4 patients were carrying the MMP-2, -9, TIMP-2 or TNF-α mutant genotype, respectively, and were combined with the heterozygote group for statistical purposes. Differences in phenotype between genotypes were tested for statistical significance by Kruskal-Wallis/Mann-Whitney U (onset) or Chi-Square test (colon involvement/fistulae and stricture development).
P ≤ 0.03 vs 5T6T and 6T6T combined,
P = 0.025 vs TC and CC combined.